BRAF檢驗市場:各市場區隔規模，佔有率，法律規章，償付，2033年為止的預測

使用活檢組織進行 BRAF 測試以檢測 BRAF V600 突變蛋白或 BRAF 基因突變，結果有望指導黑色素瘤的治療。 BRAF 基因屬於一組稱為癌基因的基因。當癌症基因突變時，它們會導致正常細胞癌變。

BRAF 基因為製造將特定訊號從細胞外傳遞到細胞核的蛋白質提供了指導。該蛋白是 RAF/MAPK 訊號通路的一部分，該通路控制多種重要的細胞功能。特別是，RAF/MAPK 路徑指導細胞發育和分裂（增殖）、細胞發育成特定功能（分化）、細胞運動（遷移）和細胞破裂（凋亡）的步驟。

本報告提供全球BRAF檢驗市場相關資料詳細考察，提供市場上競爭情形，SWOT分析，到2033年為止的市場預測，地區，各國的趨勢等資訊。

目錄

已上市的BRAF檢驗和不斷變化的競爭格局

• 主要的產業趨勢洞察
• BRAF檢驗的各市場區隔整體市場收益和2015年～2033年的市場展望
• 件數，平均銷售價格，市場價值相關詳細資料

世界，地區，各國洞察

• BRAF檢驗市場SWOT分析
• BRAF檢驗市場相關競爭動態的洞察和趨勢
• 各國醫療制度概要
• 各國償付政策
• 各國醫療技術相關法規狀況

BRAF Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

BRAF tests are carried out to detect either the BRAF V600 mutant protein or mutations in the BRAF gene, using biopsied tissue, the outcome of which may guide therapies to treat melanoma cancer. The BRAF gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous.

The BRAF gene gives guidelines to making a protein that transmits specific signals from outside the cell to the cell's nucleus. This protein is a piece of a signaling pathway known as the RAF/MAPK pathway, which controls a few significant cell functions. In particular, the RAF/MAPK pathway directs the development and division (proliferation) of cells, the procedure by which cells develop to specific functions (differentiation), cell movement (migration), and the implosion of cells (apoptosis).

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed BRAF Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BRAF Tests market.
• Competitive dynamics insights and trends provided for BRAF Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Roche Diagnostics International Ltd, bioMerieux SA, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Biocartis Group NV, BGI Genomics Co Ltd, and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRAF Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving BRAF Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRAF Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.